| DESCRIPTION | - ANSELL et al., Blood, (20150000), vol. 126, page 583 |
| DESCRIPTION | - DRAKE et al., BJU Int, (20130000), vol. 112, pages 1 - 17 |
| DESCRIPTION | - HAMID; CARVAJAL, Expert Opin Biol Ther, (20130000), vol. 13, no. 6, pages 847 - 61 |
| DESCRIPTION | - HAMID et al., N Engl J Med, (20130000), vol. 369, pages 134 - 144 |
| DESCRIPTION | - HODI et al., N Engl JMed, (20100000), vol. 363, pages 711 - 23 |
| DESCRIPTION | - MCDERMOTT; ATKINS, Cancer Med, (20130000), vol. 2, no. 5, pages 662 - 73 |
| DESCRIPTION | - NCCN GUIDELINES, (20140000), vol. 9 |
| DESCRIPTION | - OVERMAN M et al., Ann Oncol., (20160000), vol. 27, no. 6, pages 149 - 206 |
| DESCRIPTION | - OVERMAN M et al., J Clin Oncol., (20170000), vol. 35, no. 4S |
| DESCRIPTION | - PAWLIK et al., Dis. Markers, (20040000), vol. 20, no. 4-5, pages 199 - 206 |
| DESCRIPTION | - SJOBLOM et al., Science, (20060000), vol. 314, pages 268 - 74 |
| DESCRIPTION | - TOPALIAN et al., Curr Opin Immunol, (20120000), vol. 24, pages 207 - 12 |
| DESCRIPTION | - TOPALIAN et al., J Clin Oncol, (20140000), vol. 32, no. 10, pages 1020 - 30 |
| DESCRIPTION | - TOPALIAN et al., J Clin Oncol, (20140000), vol. 32, pages 1020 - 30 |
| DESCRIPTION | - TOPALIAN et al., N Engl J Med, (20120000), vol. 366, pages 2443 - 54 |
| DESCRIPTION | - TOPALIAN et al., NEngl J Med, (20120000), vol. 366, pages 2443 - 54 |
| DESCRIPTION | - WANG et al., Cancer Immunol Res, (20140000), vol. 2, no. 9, pages 846 - 56 |
| DESCRIPTION | - WANG et al., Cancer Immunol Res, (20140000), vol. 2, pages 846 - 56 |
| DESCRIPTION | - WANG et al., "In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates", Cancer Imm Res,, (20140000), vol. 2, no. 9, doi:doi:10.1158/2326-6066.CIR-14-0040, pages 846 - 56, XP055206944 |
| INTERNATIONAL-SEARCH-REPORT | - Anonymous, "An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread - Full Text View - ClinicalTrials.gov", (20131218), URL: https://clinicaltrials.gov/ct2/show/NCT02060188, (20170712), XP055390376 [X] 1-5,7 * the whole document * [Y] 8-15 |
| INTERNATIONAL-SEARCH-REPORT | - Anonymous, "Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors - Full Text View - ClinicalTrials.gov", (20130610), URL: https://clinicaltrials.gov/ct2/show/NCT01876511, (20170712), XP055390377 [X] 1-6 * the whole document * [Y] 7-15 |
| INTERNATIONAL-SEARCH-REPORT | - ZUMWALT TIMOTHY J ET AL, "Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives.", (20150601), pages 1 - 28, HHS Public Author Manuscript, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591512/, (20170719), XP055389454 [A] 1-15 * abstract * * Published in final edited form as: Curr Colorectal Cancer Rep. 2015 Jun 1; 11(3): 125-140. Published online 2015 Jun 29. doi: 10.1007/s11888-015-0269-2 * |
| INTERNATIONAL-SEARCH-REPORT | - LI STEPHEN K H ET AL, "Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored", TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, GB, (20160309), vol. 22, no. 4, doi:10.1016/J.MOLMED.2016.02.003, ISSN 1471-4914, pages 274 - 289, XP029490434 [A] 1-15 * the whole document * |
| INTERNATIONAL-SEARCH-REPORT | - MATTHEW W ROSENBAUM ET AL, "PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes", MODERN PATHOLOGY, GB, (20160520), vol. 29, no. 9, doi:10.1038/modpathol.2016.95, ISSN 0893-3952, pages 1104 - 1112, XP055389478 [Y] 1-15 * the whole document * |
| INTERNATIONAL-SEARCH-REPORT | - DUNG T. LE ET AL, "PD-1 Blockade in Tumors with Mismatch-Repair Deficiency", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM -, (20150625), vol. 372, no. 26, doi:10.1056/NEJMoa1500596, ISSN 0028-4793, pages 2509 - 2520, XP055390373 [X] 1-7 * the whole document * [Y] 8-15 |
| INTERNATIONAL-SEARCH-REPORT | - GUIDO KROEMER ET AL, "Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?", ONCOIMMUNOLOGY, (20150605), vol. 4, no. 7, doi:10.1080/2162402X.2015.1058597, page e1058597, XP055389458 [Y] 1-15 * the whole document * |
| INTERNATIONAL-SEARCH-REPORT | - J. DURAISWAMY ET AL, "Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors", CANCER RESEARCH, (20130615), vol. 73, no. 12, doi:10.1158/0008-5472.CAN-12-4100, ISSN 0008-5472, pages 3591 - 3603, XP055218335 [Y] 1-15 * the whole document * |
| INTERNATIONAL-SEARCH-REPORT | - J. C. DUDLEY ET AL, "Microsatellite Instability as a Biomarker for PD-1 Blockade", CLINICAL CANCER RESEARCH, US, (20160214), vol. 22, no. 4, doi:10.1158/1078-0432.CCR-15-1678, ISSN 1078-0432, pages 813 - 820, XP055389482 [Y] 1-15 * the whole document * |
| INTERNATIONAL-SEARCH-REPORT | - N. J. LLOSA ET AL, "The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints", CANCER DISCOVERY, US, (20150101), vol. 5, no. 1, doi:10.1158/2159-8290.CD-14-0863, ISSN 2159-8274, pages 43 - 51, XP055349318 [Y] 1-15 * the whole document * |
| INTERNATIONAL-SEARCH-REPORT | - MARK J. SELBY ET AL, "Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology", PLOS ONE, (20160909), vol. 11, no. 9, doi:10.1371/journal.pone.0161779, pages 1 - 19, XP055389440 [XP] 1-15 * the whole document * |
| INTERNATIONAL-SEARCH-REPORT | - MICHAEL A. POSTOW, "Managing Immune Checkpoint-Blocking Antibody Side Effects", AMERICAN SOCIETY OF CLINICAL ONCOLOGY EDUCATIONAL BOOK, (20150601), vol. 35, doi:10.14694/EdBook_AM.2015.35.76, ISSN 1548-8748, pages 76 - 83, XP055320216 [Y] 1-15 * the whole document * |
| OPPOSITION | - Anonymous, "Colosigmoidostomy ", Stedman's Medical Dictionary, (20000101), page 382, XP055952170 |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT02231749 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal C (CheckMate 214)", ClinicalTrials.gov archive, (20160525), pages 1 - 15, ClinicalTrials.gov archive , URL: https://clinicaltrials.gov/ct2/history/NCT02231749?A=41&B=41&C=merged#StudyPageTop, (20220810), XP055950558 |
| OPPOSITION | - Anonymous, "List of medical abbreviations: Q - Wikipedia", (20220312), pages 1 - 2, URL: https://en.wikipedia.org/w/index.php?title=List_of_medical_abbreviations:_Q&oldid=1076737937, (20220810), XP055950339 |
| OPPOSITION | - Anonymous, "medical definition of Colorectal ", merriam webster, (20160522), XP055952168 |
| OPPOSITION | - Anonymous, "Study Record Versions History of Changes for Study: NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Co That Has Come Back or Has Spread (CheckMate142)", Clinicaltrials.gov NCT02060188, (20170601), Clinicaltrials.gov NCT02060188, URL: https://clinicaltrials.gov/ct2/history/NCT02060188?V_73=View#StudyPageTop, (20220809), XP055949944 |
| OPPOSITION | - Anonymous, "Study Record Versions History of Changes for Study: NCT02060188 A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)", Clinicaltrials.gov NCT02060188, (20160525), Clinicaltrials.gov NCT02060188, URL: https://clinicaltrials.gov/ct2/history/NCT02060188?V_1=View#Study, (20220809), XP055949943 |
| OPPOSITION | - Anonymous, "the genetics of cancer ", cancer.net, (20160523), XP055952165 |
| OPPOSITION | - Antonia Scott J, "Checkmate 032: Nivolumab (N)alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).", Journal of Clinical Oncology, (20160520), vol. 34, no. 15 -supp, pages 1 - 3, XP055956169 |
| OPPOSITION | - Antonia Scott J., Et Al, "Nivolumab (anti-PD-1;BMS-936558, ONO-4538) and pilimumab in first-line NSCLC: Interim phase I results", Journal of Clinical Oncology, (20140520), vol. 32, no. 15-supp, pages 1 - 4, XP055956175 |
| OPPOSITION | - BELLIZZI AM et al., "Colorectal cancer due to deficiency in DNA mismatch repair function: a review", Adv Anat Pathol, (20090000), vol. 16, no. 6, pages 405 - 17, XP055952175 |
| OPPOSITION | - BOLAND C R, ET AL., "A NATIONAL CANCER INSTITUTE WORKSHOP ON MICROSATELLITE INSTABILITY FOR CANCER DETECTION AND FAMILIAL PREDISPOSITION: DEVELOPMENT OF INTERNATIONAL CRITERIA FOR THE DETERMINATION OF MICROSATELLITE INSTABILITY IN COLORECTAL CANCER", Cancer research, American Association for Cancer Research, US, US , (19981115), vol. 58, no. 22, ISSN 0008-5472, pages 5248 - 5257, XP001080197 |
| OPPOSITION | - Boland, C.R. ; Goel, A., "Microsatellite Instability in Colorectal Cancer", Gastroenterology, Elsevier Inc., US, US , (20100601), vol. 138, no. 6, ISSN 0016-5085, pages 2073 - 2087.e3, XP027022252 |
| OPPOSITION | - Boland, C.R. ; Goel, A., "Microsatellite Instability in Colorectal Cancer", Gastroenterology, US , (20100601), vol. 138, no. 6, ISSN 0016-5085, pages 2073 - 2087.e3, XP027022252 |
| OPPOSITION | - Bruce Alberts, Dennis Bray, Karen Hopkin, Alexander Johnson , Julian Lewis , Martin Raff , Keith Roberts , Peter Walter , "how genes and genomes evolve ", Essential Cell Biology, (20040101), XP055952166 |
| OPPOSITION | - "Chapter 4 - The Medical Report", Marjorie Canfield Willis, Medical Terminology, The Language of Health Care Second Edition, Lippincott Williams & Wilkins , (20060101), page 3pp, 93, XP055950539 |
| OPPOSITION | - Clinical Trials, "History of changes for Study: NCT01928394. A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors", (20160525), pages 1 - 12, XP055956183 |
| OPPOSITION | - "Colorectal Cancer", Michael Peters, A-Z Family Medical Encyclopedia, Sixth Edition, Dorling Kindersley Ltd, London, (20140101), page 3pp, 186, XP055950543 |
| OPPOSITION | - Dietmaier, W, "Mikrosatelliteninstabilität", der pathologie, (20100101), vol. 31, no. SUPP 2 , pages 268 - 273, XP055952189 |
| OPPOSITION | - Eduardo Vilar, Stephen B. Gruber , "Microsatellite instability in colorectal cancer-the stable evidence", Nat Rev Clin Oncol, (20100301), vol. 7, pages 153 - 162, XP055952173 |
| OPPOSITION | - Fda, "OPDIVO (nivolumab) injection, for intravenous use", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20150901), pages 1 - 34, HIGHLIGHTS OF PRESCRIBING INFORMATION, (20220809), XP055949954 |
| OPPOSITION | - GIARDIELLO FM et al., "AGA technical review on hereditary colorectal cancer and genetic testing", Gastroenterology, (20010000), vol. 121, no. 1, pages 198 - 213, XP055952196 |
| OPPOSITION | - Hoffman Jason, "Nivolumab ± Ipilimumab Demonstrates Encouraging Activity, Survival in mCRC", Cancer Therapy Advisor -ASCO 2016 press release, (20160605), pages 1 - 5, Cancer Therapy Advisor -ASCO 2016 press release, (20220830), XP055956193 |
| OPPOSITION | - Jason M. Broderick, "Nivolumab/Ipilimumab Combo More Effective than Monotherapy in mCRC", Targeted Oncology, (20160615), pages 1 - 4, Targeted Oncology, URL: https://www.targetedonc.com/view/nivolumabipilimumab-combo-more-effective-than-monotherapy-in-mcrc, (20220810), XP055950562 |
| OPPOSITION | - JASS JR, "Towards a molecular classification of colorectal cancer", Int J Colorectal Dis, (19990000), vol. 14, no. 4-5, pages 194 - 200, XP055952185 |
| OPPOSITION | - Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean Jacques Grob, C. Lance Cowey, Christopher Lao, Dirk Schadendorf, Pier Francesco Ferrucci, Michael Smylie, Reinhard Dummer, Andrew Hill, John B. A. G. Haanen, Michele Maio, Grant A. Mcarthur, Dana Walker, Joel Jiang, Christine E. Horak, James M. G. Larkin, F. Stephen Hodi, "Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). Meeting Abstract", Journal of Clinical Oncology / 2016 ASCO Annual Meeting, (20160520), vol. 34, no. 15 suppl., page 9505, XP055950345 |
| OPPOSITION | - Karahan Birgül, Argon Asuman, Yıldırım Mehmet, Vardar Enver, "Relationship between MLH-1, MSH-2, PMS-2, MSH-6 expression and clinicopathological features in colorectal cancer", Int J Clin Exp Pathol, (20150401), vol. 8, no. 4, pages 4044 - 4053, XP055950349 |
| OPPOSITION | - Lahcen Jaafar, Hernan Flores-Rozas, "Elucidating the role of human mismatch repair factor hMLH3", Cancer Biology & Therapy, (20090715), vol. 8, no. 14, pages 1421 - 1423, XP055950546 |
| OPPOSITION | - Matthew David Hellmann, Scott N. Gettinger, Jonathan Wade Goldman, Julie R. Brahmer, Hossein Borghaei, Laura Q. Chow, Neal Ready, David E. Gerber, Rosalyn A. Juergens, Frances A. Shepherd, Scott Andrew Laurie, Ye Zhou, William J. Geese, Shruti Agrawal, Xuemei Li, Scott Joseph Antonia, "CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. ", Journal of Clinical Oncology / 2016 ASCO Annual Meeting I, (20160520), vol. 34, no. 15 suppl., page 3001, XP055950366 |
| OPPOSITION | - OVERMAN, M. J. et al., J. Clin. Oncol., (20160520), vol. 34, page 3501, XP055949728 |
| OPPOSITION | - OVERMAN, MJ et al., "Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI- H): CheckMate-142 interim results", J. Clin. Oncol., (20160520), vol. 34, pages 3501 - 3501 |
| OPPOSITION | - Overman M J, "gastrointestinal tumours, colorectal", Annals of Oncology, (20160101), vol. 27, no. Supp 6, pages vi149 - vi206, XP055956191 |
| OPPOSITION | - Overman M. J., Scott Kopetz, Raymond S. Mcdermott, Joseph Leach, Sara Lonardi, Heinz-Josef Lenz, "Nivolumab /- ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and with- out high microsatellite instability (MSI-H): CheckMate-142 interim results", 2016 ASCO Annual Meeting. Journal of Clinical Oncology, (20160520), vol. 34, no. 15 suppl, page 3501, XP055949728 |
| OPPOSITION | - Raedler Lisa A., "Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma", American Health & Drug Benefits, (20150301), vol. 8, pages 180 - 183, XP055950358 |
| OPPOSITION | - VILAR E et al., "Microsatellite instability in colorectal cancer-the stable evidence", Nat Rev Clin Oncol, (20100000), vol. 7, no. 3, pages 153 - 162, XP055952173 |
| OPPOSITION | - Hamid Omid; Carvajal Richard D, "Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy", Expert opinion on biological therapy, UK , (20130601), vol. 13, no. 6, doi:10.1517/14712598.2013.770836, ISSN 1744-7682, pages 847 - 861, XP008170016 |
| OPPOSITION | - David F. Mcdermott, Michael B. Atkins, "PD-1 as a potential target in cancer therapy", Cancer Medicine, Wiley, (20130721), vol. 2, no. 5, doi:10.1002/cam4.106, ISSN 20457634, pages 662 - 673, XP055157252 |
| OPPOSITION | - Boland C. Richard, "Roles of the DNA mismatch repair genes in colorectal tumorigenesis", International Journal of Cancer, John Wiley & Sons, Inc., US, US , (19960220), vol. 69, no. 1, doi:10.1002/(SICI)1097-0215(19960220)69:1<47::AID-IJC11>3.0.CO;2-H, ISSN 0020-7136, pages 47 - 49, XP055950549 |
| OPPOSITION | - LOUGHREY MB et al., "Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer", Fam Cancer, (20070000), vol. 6, no. 3, doi:10.1007/s10689-007-9124-1, pages 301 - 10, XP037830754 |
| OPPOSITION | - GATALICA Z et al., "High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine", Fam Cancer, (20160000), vol. 15, no. 3, doi:10.1007/s10689-016-9884-6, pages 405 - 412, XP035974751 |
| OPPOSITION | - WEISSMAN SM et al., "Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review", J Genet Coun s, (20110000), vol. 20, no. 1, doi:10.1007/s10897-010-9325-x, pages 5 - 19, XP019881509 |
| OPPOSITION | - SUNSHINE, J et al., Curr. Opin. Pharmacol., (20150000), vol. 23, pages 32 - 38, XP055304528 |
| OPPOSITION | - BUECHER B et al., "Role of microsatellite instability in the management of colorectal cancers", Dig Liver Dis, (20130000), vol. 45, no. 6, doi:10.1016/j.dld.2012.10.006, pages 441 - 9, XP028550031 |
| OPPOSITION | - Matthew W Rosenbaum, Jacob R Bledsoe, Vicente Morales-Oyarvide, Tiffany G Huynh, Mari Mino-Kenudson, "PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes", Modern Pathology, Nature Publishing Group, GB, GB , (20160901), vol. 29, no. 9, doi:10.1038/modpathol.2016.95, ISSN 0893-3952, pages 1104 - 1112, XP055389478 |
| OPPOSITION | - Celine Boutros, Ahmad Tarhini, Emilie Routier, Olivier Lambotte, Francois Leroy Ladurie, Franck Carbonnel, Hassane Izzeddine, Aurelien Marabelle, Stephane Champiat, Armandine Berdelou, Emilie Lanoy, Matthieu Texier, Cristina Libenciuc, Alexander M. M. Eggermont, Jean-Charles Soria, Christine Mateus, Caroline Robert, "Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination", NATURE REVIEWS CLINICAL ONCOLOGY, Nature, NY, US, NY, US , vol. 13, no. 8, doi:10.1038/nrclinonc.2016.58, ISSN 1759-4774, pages 473 - 486, XP055393186 |
| OPPOSITION | - TOPALIAN SUZANNE L ET AL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.", New England Journal of Medicine, US , (20120628), vol. 366, no. 26, doi:10.1056/NEJMoa1200690, ISSN 1533-4406, pages 2443 - 2454, XP002767416 |
| OPPOSITION | - Jedd D. Wolchok, Harriet Kluger, Margaret K. Callahan, Michael A. Postow, Naiyer A. Rizvi, Alexander M. Lesokhin, Neil H. Segal, Charlotte E. Ariyan, Ruth-Ann Gordon, Kathleen Reed, Matthew M. Burke, Anne Caldwell, Stephanie A. Kronenberg, Blessing U. Agunwamba, Xiaoling Zhang, Israel Lowy, Hector David Inzunza, William Feely, Christine E. Horak, Quan Hong, Alan J. Korman, Jon M. Wigginton, Ashok Gupta, Mario Sznol, "Nivolumab plus Ipilimumab in Advanced Melanoma", New England Journal of Medicine, (20130711), vol. 369, no. 2, doi:10.1056/NEJMoa1302369, ISSN 00284793, pages 122 - 133, XP055182024 |
| OPPOSITION | - Jedd D. Wolchok, Harriet Kluger, Margaret K. Callahan, Michael A. Postow, Naiyer A. Rizvi, Alexander M. Lesokhin, Neil H. Segal, Charlotte E. Ariyan, Ruth-Ann Gordon, Kathleen Reed, Matthew M. Burke, Anne Caldwell, Stephanie A. Kronenberg, Blessing U. Agunwamba, Xiaoling Zhang, Israel Lowy, Hector David Inzunza, William Feely, Christine E. Horak, Quan Hong, Alan J. Korman, Jon M. Wigginton, Ashok Gupta, Mario Sznol, "Nivolumab plus Ipilimumab in Advanced Melanoma", New England Journal of Medicine, New England Journal of Medicine, (20130711), vol. 369, no. 2, doi:10.1056/NEJMoa1302369, ISSN 00284793, pages 122 - 133, XP055182024 |
| OPPOSITION | - Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Gangadhar, Amita Patnaik, Hassane Zarour, Anthony M. Joshua, Kevin Gergich, Jeroen Elassaiss-Schaap, Alain Algazi, Christine Mateus, Peter Boasberg, Paul C. Tumeh, Bartosz Chmielowski, Scot W. Ebbinghaus, Xiaoyun Nicole Li, S. Peter Kang, Antoni Ribas, "Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma", New England Journal of Medicine, New England Journal of Medicine, (20130711), vol. 369, no. 2, doi:10.1056/NEJMoa1305133, ISSN 00284793, pages 134 - 144, XP055182016 |
| OPPOSITION | - Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C. Scott, Martin Gutierrez, Stephen J. Schuster, Michael M. Millenson, Deepika Cattry, Gordon J. Freeman, Scott J. Rodig, Bjoern Chapuy, Azra H. Ligon, Lili Zhu, Joseph F. Grosso, Su Young Kim, John M. Timmerman, Margaret A. Shipp, Philippe Armand, "PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma", The New England journal of medicine, Massachusetts Medical Society, US, US , (20150122), vol. 372, no. 4, doi:10.1056/NEJMoa1411087, ISSN 0028-4793, pages 311 - 319, XP055239003 |
| OPPOSITION | - Michael A. Postow et al, "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma", The New England journal of medicine, US , (20150521), vol. 372, doi:10.1056/NEJMoa1414428, ISSN 0028-4793, pages 2006 - 2017, XP002761464 |
| OPPOSITION | - LE DUNG T ET AL, "PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20150625), vol. 372, no. 26, doi:10.1056/NEJMoa1500596, ISSN 1533-4406, pages 2509 - 2520, XP002780490 |
| OPPOSITION | - LE DUNG T ET AL, "PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.", New England Journal of Medicine, US , (20150625), vol. 372, no. 26, doi:10.1056/NEJMoa1500596, ISSN 1533-4406, pages 2509 - 2520, XP002780490 |
| OPPOSITION | - James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski, Pier F. Ferrucci, Andrew Hill, John Wagstaff, Matteo S. Carlino, John B. Haanen, Michele Maio, Ivan Marquez-Rodas, Grant A. Mcarthur, Paolo A. Ascierto, Georgina V. Long, Margaret K. Callahan, Michael A. Postow, Kenneth Grossmann, Mario Sznol, Brigitte Dreno, Lars Bastholt, Arvin Yang, Linda M. Rollin, Christine Horak, F. Stephen Hodi, Jedd D. Wolchok, "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma", The New England journal of medicine, Massachusetts Medical Society, US, US , (20150702), vol. 373, no. 1, doi:10.1056/NEJMoa1504030, ISSN 0028-4793, pages 23 - 34, XP055316141 |
| OPPOSITION | - Guido Kroemer, Lorenzo Galluzzi, Laurence Zitvogel, Wolf Hervé Fridman, "Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?", OncoImmunology, (20150703), vol. 4, no. 7, doi:10.1080/2162402X.2015.1058597, page e1058597, XP055389432 |
| OPPOSITION | - Guido Kroemer, Lorenzo Galluzzi, Laurence Zitvogel, Wolf Hervé Fridman, "Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?", OncoImmunology, (20150703), vol. 4, no. 7, doi:10.1080/2162402X.2015.1058597, page e1058597, XP055389458 |
| OPPOSITION | - Hammers H., Plimack E.R., Infante J.R., Ernstoff M., Rini B.I., Mcdermott D.F., Razak A., Pal S.K., Voss M., Sharma P., Kollmannsberger C.K., Heng D., Shen Y., Kurland J., Spratlin J., Gagnier P., Amin A., "Phase I Study of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma (Mrcc)", Annals of Oncology, Kluwer Dordrecht, NL, NL , (20140901), vol. 25, doi:10.1093/annonc/mdu342.3, ISSN 0923-7534, page iv361, XP055950361 |
| OPPOSITION | - Elizabeth I. Buchbinder, Anupam Desai, "CTLA-4 and PD-1 Pathways : Similarities, Differences, and Implications of Their Inhibition", AMERICAN JOURNAL OF CLINICAL ONCOLOGY (CANCER CLINICAL TRIALS)., RAVEN PRESS LTD., NEW YORK NY., US, US , (20160201), vol. 39, no. 1, doi:10.1097/COC.0000000000000239, ISSN 0277-3732, pages 98 - 106, XP055393184 |
| OPPOSITION | - Elizabeth I. Buchbinder, Anupam Desai, "CTLA-4 and PD-1 Pathways : Similarities, Differences, and Implications of Their Inhibition", AMERICAN JOURNAL OF CLINICAL ONCOLOGY (CANCER CLINICAL TRIALS), US , (20160201), vol. 39, no. 1, doi:10.1097/COC.0000000000000239, ISSN 0277-3732, pages 98 - 106, XP055393184 |
| OPPOSITION | - POULOGIANNIS G et al., "DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome", Histopathology, (20100000), vol. 56, no. 2, doi:10.1111/j.1365-2559.2009.03392.x, pages 167 - 79, XP071616137 |
| OPPOSITION | - SHARMA, P. et al., Science, (20150000), vol. 348, pages 56 - 61, XP055402824 |
| OPPOSITION | - Pawlik Timothy M., Raut Chandrajit P., Rodriguez-Bigas Miguel A., "Colorectal Carcinogenesis: MSI-H Versus MSI-L", Disease Markers, WILEY, CHICHESTER., GB, GB , (20040101), vol. 20, no. 4-5, doi:10.1155/2004/368680, ISSN 0278-0240, pages 199 - 206, XP055949952 |
| OPPOSITION | - DURAISWAMY et al., "Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T cell rejection function in tu- mors", Cancer Research, (20130615), vol. 73, no. 12, doi:10.1158/0008-5472.CAN-12-4100, pages 3591 - 3603, XP055218335 |
| OPPOSITION | - J. C. Dudley, M.-T. Lin, D. T. Le, J. R. Eshleman, "Microsatellite Instability as a Biomarker for PD-1 Blockade", Clinical Cancer Research, Association for Cancer Research, US, US, (20160215), vol. 22, no. 4, doi:10.1158/1078-0432.CCR-15-1678, ISSN 1078-0432, pages 813 - 820, XP055389482 |
| OPPOSITION | - N. J. Llosa, M. Cruise, A. Tam, E. C. Wicks, E. M. Hechenbleikner, J. M. Taube, R. L. Blosser, H. Fan, H. Wang, B. S. Luber, M. Zhang, N. Papadopoulos, K. W. Kinzler, B. Vogelstein, C. L. Sears, R. A. Anders, D. M. Pardoll, F. Housseau, "The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20150101), vol. 5, no. 1, doi:10.1158/2159-8290.CD-14-0863, ISSN 2159-8274, pages 43 - 51, XP055349318 |
| OPPOSITION | - N. J. Llosa, M. Cruise, A. Tam, E. C. Wicks, E. M. Hechenbleikner, J. M. Taube, R. L. Blosser, H. Fan, H. Wang, B. S. Luber, M. Zhang, N. Papadopoulos, K. W. Kinzler, B. Vogelstein, C. L. Sears, R. A. Anders, D. M. Pardoll, F. Housseau, "The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20150101), vol. 5, no. 1, doi:10.1158/2159-8290.CD-14-0863, ISSN 2159-8274, pages 43 - 51, XP055390935 |
| OPPOSITION | - N. J. Llosa, M. Cruise, A. Tam, E. C. Wicks, E. M. Hechenbleikner, J. M. Taube, R. L. Blosser, H. Fan, H. Wang, B. S. Luber, M. Zhang, N. Papadopoulos, K. W. Kinzler, B. Vogelstein, C. L. Sears, R. A. Anders, D. M. Pardoll, F. Housseau, "The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints", CANCER DISCOVERY, US , (20150101), vol. 5, no. 1, doi:10.1158/2159-8290.CD-14-0863, ISSN 2159-8274, pages 43 - 51, XP055390935 |
| OPPOSITION | - Y. Xiao, Freeman G. J., "The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20150101), vol. 5, no. 1, doi:10.1158/2159-8290.CD-14-1397, ISSN 2159-8274, pages 16 - 18, XP055271983 |
| OPPOSITION | - Matthew Taylor et al, "Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032", Journal for ImmunoTherapy of Cancer, London, UK , (20151104), vol. 3, no. 2, doi:10.1186/2051-1426-3-S2-P376, pages 1 - 2, XP021235542 |
| OPPOSITION | - Matthew Taylor;Scott Antonia;Johanna Bendell;Emiliano Calvo;Dirk Jäger;Filippo de Braud;PatrickA Ott;MCatherine Pietanza;Leora Horn;DungT Le;MichaelA Morse;JoséA López-Martin;PaoloA Ascierto;Olaf Christensen;JasonS Simon;Chen-Sheng Lin;JosephPaul Eder, "Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032", Journal for ImmunoTherapy of Cancer, BioMed Central Ltd, London, UK, London, UK , (20151104), vol. 3, no. 2 Suppl, doi:10.1186/2051-1426-3-S2-P376, pages 1 - 2, XP021235542 |
| OPPOSITION | - Demetri George D., Chawla Sant P., Von Mehren Margaret, Ritch Paul, Baker Laurence H., Blay Jean Y., Hande Kenneth R., Keohan Mary L., Samuels Brian L., Schuetze Scott, Lebedinsky Claudia, Elsayed Yusri A., Izquierdo Miguel A., Gómez Javier, Park Youn C., Le Cesne Axel, "Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20090901), vol. 27, no. 25, doi:10.1200/JCO.2008.21.0088, ISSN 0732-183X, pages 4188 - 4196, XP055950356 |
| OPPOSITION | - Hammers Hans J., Plimack Elizabeth R., Infante Jeffrey R., Rini Brian I., Mcdermott David F., Ernstoff Marc, Voss Martin Henner, Sharma Padmanee, Pal Sumanta Kumar, Razak Albiruni R. A., Kollmannsberger Christian K., Heng Daniel Yick Chin, Spratlin Jennifer L., Shen Yun, Gagnier Paul, Amin Asim, "Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20150520), vol. 33, no. 15_suppl, doi:10.1200/jco.2015.33.15_suppl.4516, ISSN 0732-183X, pages 4516 - 4516, XP055949948 |
| OPPOSITION | - Hammers Hans J., Plimack Elizabeth R., Sternberg Cora, Mcdermott David F., Larkin James M. G., Ravaud Alain, Rini Brian I., Sharma Padmanee, Bhagavatheeswaran Prabhu, Gagnier Paul, Motzer Robert, "CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20150520), vol. 33, no. 15_suppl, doi:10.1200/jco.2015.33.15_suppl.tps4578, ISSN 0732-183X, pages TPS4578 - TPS4578, XP055949949 |
| OPPOSITION | - Banerjee Rebecca, Mosley R. Lee, Reynolds Ashley D., Dhar Alok, Jackson-Lewis Vernice, Gordon Paul H., Przedborski Serge, Gendelman Howard E., "Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice", PLoS ONE, (20080723), vol. 3, no. 7, doi:10.1371/journal.pone.0002740, pages e2740-1 - e2740-16, XP055950354 |
| OPPOSITION | - Mark J. Selby, Engelhardt John J., Johnston Robert J., Lu Li-Sheng, Han Minhua, Thudium Kent, Yao Dapeng, Quigley Michael, Valle Jose, Wang Changyu, Chen Bing, Cardarelli Pina M., Blanset Diann, Korman Alan J., "Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology", PLOS ONE, (20160909), vol. 11, no. 9, doi:10.1371/journal.pone.0161779, page e0161779, XP055389440 |
| OPPOSITION | - Michael A. Postow, "Managing Immune Checkpoint-Blocking Antibody Side Effects", Educational Book, American Society of Clinical Oncology, US, US , (20150601), vol. 35, doi:10.14694/EdBook_AM.2015.35.76, ISSN 1548-8748, pages 76 - 83, XP055320216 |
| OPPOSITION | - Pino Maria S, Chung Daniel C, "Microsatellite instability in the management of colorectal cancer", Expert Review of Gastroenterology & Hepatology, UK , (20110601), vol. 5, no. 3, doi:10.1586/egh.11.25, ISSN 1747-4124, pages 385 - 399, XP055923379 |
